<DOC>
	<DOCNO>NCT00241644</DOCNO>
	<brief_summary>The primary objective study determine GSK Biologicals ' human rotavirus ( HRV ) vaccine ( pool HRV group ) give concomitantly routine expand program immunisation ( EPI ) vaccination prevent severe rotavirus gastroenteritis ( ≥11 20-point Vesikari scoring system [ Ruuska , 1990 ] ) cause circulate wild-type RV strain period 2 week last dose HRV vaccine placebo Visit 5 . The primary objective reach low limit 95 % confidence interval ( CI ) vaccine efficacy &gt; 0 % . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Vaccine Efficacy Against Rotavirus Diarrhea ; Vaccine Given With Routine Childhood Vaccinations Healthy African Infants</brief_title>
	<detailed_description>The study three group : Rotarix 3-Dose Group , Rotarix 2-Dose Group Placebo Group . Three-dose immunisation administer healthy infant approximately 6 , 10 , 14 week age . Routine EPI vaccination administer concomitantly study vaccine . This study also evaluate immunogenicity safety relative placebo .</detailed_description>
	<mesh_term>Rotavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol enrol study . A male female child , include , 5 10 week age time first study vaccination . Written inform consent obtain parent guardian subject legal age Healthy subject establish medical history clinical examination enter study . In South Africa , birth weight &gt; 2000 gram weight unknown , gestation period &gt; 36 week . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product Planned administration vaccine foreseen study protocol within 14 day dose study vaccine ( ) end 14 day . Chronic administration ( defined 14 day ) immunosuppressant since birth . History use experimental rotavirus vaccine . Previous routine vaccination except Bacille CalmetteGuérin ( BCG ) , hepatitis B virus ( HBV ) oral poliovirus ( OPV ) vaccination birth Any clinically significant history chronic gastrointestinal disease include uncorrected congenital malformation gastrointestinal tract , intussusception medical condition determine serious investigator . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination History allergic disease reaction likely exacerbated component vaccine . Acute disease time enrolment . Gastroenteritis within 7 day precede first study vaccine administration Previous confirm occurrence rotavirus gastroenteritis ( RV GE ) . A family history congenital hereditary immunodeficiency . Administration immunoglobulins and/or blood product since birth plan administration study period . History neurologic disorder seizure . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test .</criteria>
	<gender>All</gender>
	<minimum_age>5 Weeks</minimum_age>
	<maximum_age>10 Weeks</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Rotavirus gastroenteritis</keyword>
	<keyword>HRV vaccine</keyword>
</DOC>